Roflumilast Cream Cut Infant AD Itch Within 10 Minutes in INTEGUMENT-INFANT

Roflumilast cream 0.05% (Zoryve, Arcutis) delivered a ≥25% improvement in itch for 66.7% of infants with atopic dermatitis within 4 hours of the first application, according to caregiver-reported outcomes from the INTEGUMENT-INFANT trial presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Phoenix, AZ.

The trial enrolled 101 infants aged 3 to 24 months with mild-to-moderate AD. That age band matters: roflumilast cream 0.05% is currently FDA-approved only for mild-to-moderate AD in children aged 2 to 5 years. A supplemental New Drug Application seeking expansion down to infants 3 to 24 months is under review, with a PDUFA target action date of February 23, 2027.

How fast did itch relief arrive?

Fast, by topical standards. Caregivers first reported itch improvement as early as 10 minutes after the first application, with 46.6% of infants achieving a ≥25% improvement on the Dynamic Pruritus Score–25 (n=88). By 4 hours, that figure climbed to 66.7% (n=87).

On the Worst Scratch/Itch Numeric Rating Scale, 10.4% of infants reached WSI-NRS success at 24 hours (n=77) — a figure that rose to 72.7% at the last assessment (n=77).

What happened to symptom burden and quality of life?

The Patient-Oriented Eczema Measure (POEM, scored 0–28) tells the clearest story. Mean POEM fell from 14.5 at baseline — moderate severity — to 7.9 at Week 2 (n=100) and 6.5 at Week 4 (n=96). That's a 55% drop in one month, shifting the cohort from moderate to mild disease severity as rated by caregivers. The symptom reductions driving that change included bleeding, cracking, dryness, flaking, itching, weeping, and sleep loss.

Quality-of-life gains ran in two directions. On the Infants' Dermatitis Quality of Life Index (IDQoL), caregivers reported improvements in daily activities, sleep, and emotional well-being. On the Dermatitis Family Impact (DFI) questionnaire, they reported gains in family activities and relationships — a reminder that infant AD burdens the whole household, not just the patient.

Mark Boguniewicz, MD, Professor in the Department of Pediatrics at National Jewish Health and the University of Colorado School of Medicine in Denver, CO, said in a news release: "These new findings showed that alongside having a generally safe and well-tolerated profile, ZORYVE demonstrated improvements in the signs and symptoms of atopic dermatitis, as well as quality of life measurements, as reported by caregivers." He added: "These results underscore the importance of expanding treatment options to address the unique needs of this vulnerable population."

What does this change for prescribers?

Right now, nothing on the label — infants under 2 remain outside the approved indication. But the tolerability data strengthen the case pending before the FDA. Roflumilast cream 0.05% was well tolerated in the trial, with no serious adverse events and no severe treatment-emergent adverse events reported. At least 97.9% of infants showed no evidence of investigator-rated application-site irritation across all assessment timepoints — a meaningful signal in a population where skin reactivity often limits topical options.

If the sNDA is approved by the February 23, 2027 PDUFA date, PDE-4 inhibition would become a steroid-free topical option for the youngest AD cohort, with caregiver-reported onset data to support counseling on expectations within the first day of use.